

Cover Story
As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.
Cancer Policy


In Brief
Clinical Roundup


Drugs & Targets
Trending Stories
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- California Institute of Regenerative Medicine and Cancer Research: A promise broken?
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - Bernie Lewinsky’s collection of artifacts captures “the learning curve” of radiation oncology
- Sustaining community oncology through nonprofit structures and shared technology infrastructure

















